Objective To enhance the standardization rate of anticancer drug treatment records.Methods Based on the PDCA cycle quality management tool,C hospital developed and implemented the expert consensus on the Writing Standards for Medical Records of Anticancer Drug Treatment,and continuously monitored the record standard rate.x2 test,Fisher exact probability method and Mann-Kendall trend test were used to analyze the monitoring data.Results After publicity,training,quality control and inclusion in performance assessment,C hospital record standard rate improved rapidly,surpassed 99％in April 2023 and remaining stable thereafter.Before and after the dissemination of the management experience in District H of Beijing,the standardization rate of anticancer drug treatment records increased from 56.99％in the first quarter of 2023 to 72.82％in the first quarter of 2024.An upward trend was observed in the standardization rate of whether there is an evaluation of adverse reactions.Conclusion The standardization rate of anticancer drug treatment records based on PDCA cycle has improved.However,continuous monitoring and improvement of the standardization rate within the region are still required in the future.

Objective To enhance the standardization rate of anticancer drug treatment records.Methods Based on the PDCA cycle quality management tool,C hospital developed and implemented the expert consensus on the Writing Standards for Medical Records of Anticancer Drug Treatment,and continuously monitored the record standard rate.x2 test,Fisher exact probability method and Mann-Kendall trend test were used to analyze the monitoring data.Results After publicity,training,quality control and inclusion in performance assessment,C hospital record standard rate improved rapidly,surpassed 99％in April 2023 and remaining stable thereafter.Before and after the dissemination of the management experience in District H of Beijing,the standardization rate of anticancer drug treatment records increased from 56.99％in the first quarter of 2023 to 72.82％in the first quarter of 2024.An upward trend was observed in the standardization rate of whether there is an evaluation of adverse reactions.Conclusion The standardization rate of anticancer drug treatment records based on PDCA cycle has improved.However,continuous monitoring and improvement of the standardization rate within the region are still required in the future.

Objective: To assess the associations between the single nucleotide polymorphism (SNP) rs 12225230 of salt inducible kinase 3 ( SIK 3) and obesity/central obesity in children, and to provide evidence for screening intervention for obesity in children and adolescents. Methods: A cluster sampling of 2 030 children aged 7-18 years in Beijing were enrolled and height, weight and waist circumference were measured according to the manufacturer. The genotype frequency of SNP rs 12225230 was detected by matrix assisted laser analysis/ionization time of flight mass spectrometry (MALDI TOF MS). Logistic regression and multiple linear regression were applied to analyze the associations between SNP rs 12225230 and overweight/obesity and central obesity. Polyphen2 database was used to predict the effect of SNP rs 12225230 on the protein function of SIK 3. GTEx database was used to explore expression quantitative trait loci (eQTL) of SNP rs 12225230. Results: C allele of SNP rs 12225230 was a risk allele for obesity and severe obesity in children ( OR obesity =1.50, 95% CI=1.10-2.04, P =0.01; OR severe obesity =1.72, 95% CI=1.23-2.39, P <0.01). The SNP rs 12225230 was positively associated with waist circumference and waist height ratio ( β waist circumference =1.40, 95% CI=0.28- 2.52 , P =0.01; β waist height ratio =0.01, 95% CI=0.00-0.02, P =0.01). C allele of SNP rs 12225230 may be harmful to the function of the protein encoded by the SIK 3, and was positively related to the expression of the APOA 1 in the heart tissue. Conclusion SNP rs 12225230 is associated with obesity and central obesity in children, and SNP rs 12225230 may affect the expression of the APOA 1 in children, but its association with lipid metabolism needs to be verified

Objective: To study the relationship between rs1136410 polymorphism in poly (ADP-ribose) polymerase-1 gene (PARP-1) with obesity and non-alcoholic fatty liver disease (NAFLD) in children and adolescents, and to provide a reference for demonstrating the mechanism of obesity and NAFLD of children and adolescents and making the early prevention strategies. Methods: In total, 2 030 children and adolescents aged 7-18 years old were recruited. Anthropometric measurements were performed. Liver B-ultrasound detection were performed in a subgroup. The matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI-TDF MS) was used for genotyping the rs1136410 polymorphism. Logistic regression was used to analyze the relationship between rs1136410 polymorphism and obesity or NAFLD in children and adolescents. Results: Totally, 1 325 subjects were in non-obese group and 705 subjects were in obese group. The frequency of G allele and A allele were 43.86% and 56.14%. After adjusting for gender, age, and study population, the risk of obesity increased by 1.17 times for each additional A allele of rs1136410 polymorphism(OR=1.17, 95%CI=1.02-1.33, P=0.03). And the risk of NAFLD increased by 1.43 times for each additional A allele of rs1136410 polymorphism(OR=1.43, 95%CI=1.11-1.85, P=0.01). After further adjustment for BMI, rs1136410 polymorphism was not associated with NAFLD(P=0.70). Conclusion The rs1136410 polymorphism in PARP-1 gene is associated with obesity and NAFLD in children and adolescents. The effect of the gene polymorphism on NAFLD is mediated by BMI.